Dare Bioscience DARE
NASDAQ DARE
$0.84 -0.01 (-1.18%)
At close: Oct 2, 2026 · 4:00 PM EDT

Dare Bioscience (DARE) Gains from Sales and Divestitures (2013 - 2024)

Updated

Dare Bioscience (DARE) reported Gains from Sales and Divestitures of -$600,000 for FY2024.

Analysis

Dare Bioscience (DARE) Gains from Sales and Divestitures (2013 - 2024) Analysis & Trends

Dating back to FY2012, Dare Bioscience's Gains from Sales and Divestitures record includes 6 years.

  • The FY2024 figure ranks as the highest annual Gains from Sales and Divestitures in data going back to FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Dare Bioscience 12.74 Mn -52.72 Mn -132,343.00
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -600,000.00
Mar 31, 2017 1.50 Mn
Mar 31, 2016 -4,000.00
Dec 31, 2014 -2,000.00
Dec 31, 2013 -1,000.00
Sep 30, 2013 -5,000.00
API Access

Dare Bioscience Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=DARE&period=max&api_key=YOUR_API_KEY